Alnylam RNAi drug reverses progress of rare fatal disease: study

(Reuters) - More than half of patients with a rare, rapidly progressing fatal genetic disorder experienced significant improvement after being treated with an Alnylam Pharmaceutical Inc drug that uses gene silencing technology, according to results of a late stage study released on Thursday.